Immodulon Therapeutics announce US Orphan Drug Designation for IMM-201 in the treatment of tuberculosis

On 20 August 2010, orphan designation was granted by the FDA to Immodulon Therapeutics Ltd, United Kingdom, for heat-killed Mycobacterium vaccae (whole cell) for the treatment of tuberculosis.